Posted by Michael Wonder on 13 Dec 2025
Nucala (mepolizumab) receives positive CHMP opinion for treatment of chronic obstructive pulmonary disease
12 December 2025 - Positive opinion based on MATINEE Phase 3 trial showing significant reduction in COPD exacerbations versus placebo in addition to inhaled triple therapy.
GSK today announced that the CHMP of the EMA has recommended the approval of Nucala (mepolizumab), a monoclonal antibody targeting interleukin-5, in adults as an add-on maintenance treatment for uncontrolled chronic obstructive pulmonary disease characterised by raised blood eosinophils on a combination of an inhaled corticosteroid, a long-acting beta2-agonist and a long-acting muscarinic antagonist.
